Association between CD14 rs2569190 C>T polymorphism and ischemic stroke susceptibility: a meta-analysis based on 5,277 subjects

Figures & data

Table 1 Scale for quality evaluation

Criteria	Score
Representativeness of cases
Time, consecutive/randomly cases with clearly defined sampling frame	2
Without time or consecutive/randomly case, without clearly defined sampling frame	1
Not described	0
Source of controls
Population based	2
Hospital based or Healthy based	1
Not described	0
Hardy–Weinberg equilibrium in controls
Hardy–Weinberg equilibrium	2
Hardy–Weinberg disequilibrium	1
Not available	0
Genotyping examination
Genotyping done under “blinded” condition and repeated again	2
Genotyping done under “blinded” condition or repeated again	1
Unblinded done or not mentioned and unrepeated	0
Subjects
Number ≥500	1
Number <500	0
Association assessment
Assess association between genotypes and ischemic stroke with appropriate statistics and adjustment for confounders	2
Assess association between genotypes and ischemic stroke with appropriate statistics and without adjustment for confounders	1
Inappropriate statistics used	0

Figure 1 Flow diagram of the study selection process.

Table 2 Characteristics of case–control studies on CD14 rs2569190 C>T polymorphism and ischemic stroke risk

Study	Year	Country	Ethnicity	Control design	Genotype method	Case	Control	Genotype distribution						P for HWE	MAF	NOS evaluation
								Case			Control
								CC	CT	TT	CC	CT	TT
Ito et al^Citation17	2000	Japan	Asian	PB	PCR-RFLP	235	309	53	125	57	71	155	83	0.93	0.52	8
Grau et al^Citation23	2001	Germany	Caucasian	HB	PCR-RFLP	20	21	5	12	3	6	9	6	0.51	0.50	6
Zee et al^Citation24	2002	US	Caucasian	PB	PCR-RFLP	279	279	75	132	72	62	146	71	0.43	0.52	10
Lichy et al^Citation25	2002	Germany	Caucasian	PB	PCR-RFLP	151	149	37	75	39	73	71	35	0.02	0.39	7
Park et al^Citation26	2006	Korea	Asian	PB	PCR-RFLP	125	125	19	79	27	29	72	24	0.09	0.48	9
Lalouschek et al^Citation27	2006	USA	Caucasian	PB	PCR-RFLP	404	415	113	187	104	123	200	92	0.53	0.46	8
Kis et al^Citation28	2007	Hungary	Caucasian	HB	PCR-FLOH	59	52	20	24	15	15	20	17	0.10	0.52	7
Lin et al^Citation29	2008	China	Asian	HB	PCR-RFLP	450	450	75	213	162	61	244	145	0.01	0.59	6
Banerjee et al^Citation30	2008	India	Asian	HB	PCR-RFLP	112	212	27	50	35	36	112	64	0.27	0.57	6
Das et al^Citation31	2017	India	Asian	HB	PCR-RFLP	700	700	171	394	135	174	391	135	<0.01	0.47	7

Note: HWE is control.

Abbreviations: HB, hospital or healthy based; HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; NOS, Newcastle–Ottawa scale; PB, population based; PCR-FLOH, PCR fluorescent-labeled oligonucleotide hybridization; PCR-RFLP, PCR-restriction fragment length polymorphism.

Figure 2 OR and 95% CIs of the associations between CD14 rs2569190 C>T polymorphism and ischemic stroke susceptibility in T vs C model.

Table 3 Summary of ORs and 95% CI of CD14 rs2569190 C>T polymorphism and ischemic stroke risk

	Na	T vs C				CT vs CC				TT vs CC				CT + TT vs CC				TT vs CC + CT
		OR	95% CI	P-value	I^Citation2 (%)	OR	95% CI	P-value	I^Citation2 (%)	OR	95% CI	P-value	I^Citation2 (%)	OR	95% CI	P-value	I^Citation2 (%)	OR	95% CI	P-value	I^Citation2 (%)
Total	10	1.03	0.96–1.12	0.41	27.8	1.01	0.81–1.25	0.95	51.9	1.04	0.89–1.22	0.62	25.1	1.02	0.84–1.25	0.82	51.4	1.07	0.95–1.22	0.28	0
HWE, yes	7	1.00	0.90–1.11	0.98	0	0.96	0.79–1.15	0.64	19.5	0.99	0.80–1.23	0.93	0	0.97	0.81–1.16	0.73	15.3	1.03	0.86–1.23	0.77	0
HWE, no	3	1.13	0.90–1.41	0.28	71.5	1.11	0.67–1.84	0.67	81.6	1.19	0.77–1.84	0.43	67.4	1.16	0.72–1.87	0.54	81.6	1.12	0.94–1.34	0.21	0
Ethnicity
Asian	5	1.01	0.91–1.11	0.92	0	0.94	0.71–1.23	0.65	50.4	0.97	0.79–1.19	0.80	0	0.96	0.82–1.14	0.66	37.8	1.05	0.90–1.23	0.56	0
Caucasian	5	1.07	0.85–1.35	0.56	52.8	1.12	0.75–1.67	0.58	59.9	1.13	0.75–1.70	0.57	50.2	1.12	0.75–1.66	0.58	63.9	1.12	0.90–1.38	0.30	0
Control design
PB	5	1.11	0.93–1.32	0.23	56.6	1.18	0.84–1.65	0.33	64.2	1.22	0.88–1.70	0.24	50.0	1.20	0.87–1.67	0.27	67.0	1.10	0.92–1.32	0.30	0
HB	5	0.98	0.88–1.09	0.75	0	0.89	0.73–1.07	0.22	17.7	0.91	0.73–1.15	0.44	0	0.99	0.75–1.08	0.27	0	1.05	0.88–1.25	0.60	0
Subjects
>500	5	1.01	0.93–1.10	0.83	0	0.93	0.80–1.08	0.36	7.4	1.00	0.82–1.19	0.97	0	0.96	0.83–1.11	0.56	0	1.07	0.93–1.23	0.36	0
<500	5	1.18	0.81–1.44	0.58	57.1	1.23	0.71–2.14	0.36	63.8	1.14	0.65–2.01	0.64	55.1	1.19	0.70–2.05	0.52	67.1	1.09	0.82–1.44	0.56	0
NOS evaluation
NOS ≥8	4	1.03	0.92–1.16	0.61	0	1.00	0.82–1.23	0.98	31.9	1.07	0.84–1.36	0.59	8.3	1.02	0.84–1.25	0.81	32.0	1.06	0.87–1.29	0.56	0
NOS <8	6	1.04	0.88–1.22	0.66	48.0	1.00	0.69–1.44	0.98	65.0	1.01	0.87–1.17	0.93	43.3	1.00	0.71–1.42	0.98	64.5	1.08	0.92–1.27	0.36	5.0

Notes:

a Numbers of comparisons. I² is for heterogeneity test.

Abbreviations: HB, hospital or healthy based; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle–Ottawa scale; PB, population based.

Figure 3 Cumulative meta-analyses according to publication year in T vs C model of CD14 rs2569190 C>T polymorphism.

Figure 4 Sensitivity analysis through deleting each study to reflect the influence of the individual dataset to the pooled ORs in T vs C model of CD14 rs2569190 C>T polymorphism.

Figure 5 Funnel plot analysis to detect publication bias for T vs C model of CD14 rs2569190 C>T polymorphism.

Note: Circles represent the weight of the studies.

ItoDMurataMTanahashiNPolymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular diseaseStroke200031112661266411062291

 PubMed Web of Science ®Google Scholar

GrauAJAulmannMLichyCIncreased cytokine release by leucocytes in survivors of stroke at young ageEur J Clin Invest20013111999100611737243

 PubMed Web of Science ®Google Scholar

ZeeRYBatesDRidkerPMA prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of strokeStroke200233489289511935032

 PubMed Web of Science ®Google Scholar

LichyCMeiserHGrond-GinsbachCLipopolysaccharide receptor CD14 polymorphism and risk of stroke in a South-German populationJ Neurol2002249782182312140663

 PubMed Web of Science ®Google Scholar

ParkMHMinJYKohSBHelicobacter pylori infection and the CD14 C(-260)T gene polymorphism in ischemic strokeThromb Res2006118667167716386288

 PubMed Web of Science ®Google Scholar

LalouschekWSchillingerMHsiehKPolymorphisms of the inflammatory system and risk of ischemic cerebrovascular eventsClin Chem Lab Med200644891892316879054

 PubMed Web of Science ®Google Scholar

KisZSasKGyulaiZChronic infections and genetic factors in the development of ischemic strokeNew Microbiol200730321322017802898

 PubMed Web of Science ®Google Scholar

LinTMChenCHWuHLWangCHChenYLEngHLThe association of C (-260) – >T polymorphism in CD14 promoter and Chlamydia pneumoniae infection in ischemic stroke patientsAm J Clin Pathol2008130459560118794053

 PubMed Web of Science ®Google Scholar

BanerjeeIGuptaVAhmedTInflammatory system gene polymorphism and the risk of stroke: a case-control study in an Indian populationBrain Res Bull200875115816518158110

 PubMed Web of Science ®Google Scholar

DasSKaulSJyothyAMunshiARole of TLR4 (C1196T) and CD14 (C-260T) Polymorphisms in Development of Ischemic Stroke, Its Subtypes and Hemorrhagic StrokeJ Mol Neurosci2017633–430030728963650

 PubMed Web of Science ®Google Scholar

NorrvingBKisselaBThe global burden of stroke and need for a continuum of careNeurology2013803 Suppl 2S5S1223319486

 PubMed Web of Science ®Google Scholar